EGFR and lung carcinoma: Ang II was found to promote lung cancer progression through Epidermal Growth Factor Receptor (EGFR) transactivation, which activates the MEK/ERK pathway, or through AT1R activation, which upregulates micro RNA-21 (miRNA-21) – an oncogene – to stimulate the PI3K/AKT pathway through phosphatase and tensin homolog – a tumour suppressor – inhibition.